The second study examined the expression level of LMTK2 in blood samples of prostate cancer patients, with the aim of making use of LMTK2 level as a potential biomarker for stratification between clinically insignificant and clinically significant PCa patients [61]. This evidence concerns the gene LMTK2 and Familial prostate cancer.